Latigo Biotherapeutics Reports Third-Quarter 2026 Results and Business Highlights
The company said Phase 3 bunionectomy and open-label safety trials of onzotrigine remain on track for initiation; the source text is truncated.
Related stories
Cardlytics Reports Q3 2026 Revenue of $32.9 Million, Down 30%
Cardlytics reported a net loss of $8.9 million, adjusted EBITDA of $0.4 million and adjusted net loss per diluted share of $1.03. Monthly qualified users averaged 186.6 million, do
M impact | EQUITY | Nov 06, 2026, 02:06 PM UTC
AVITA Medical Reports Q3 Revenue Growth, Raises 2026 Guidance
AVITA Medical reported third-quarter revenue of $26.1 million, up 53% year over year and 20% sequentially. It raised full-year revenue guidance to $92 million-$94 million from $86
M impact | EQUITY | Nov 06, 2026, 02:06 PM UTC
CVRx Reports Q3 Revenue of $13.8 Million, Updates 2026 Guidance
CVRx reported third-quarter revenue of $13.8 million, including $13.0 million in U.S. revenue. It raised its full-year 2026 revenue guidance to $56 million–$57 million.
M impact | EQUITY | Nov 06, 2026, 02:06 PM UTC
KLX Energy Services Reports Q3 Revenue of $185.6 Million, Guides Q4
Third-quarter revenue rose 11% sequentially to $185.6 million. Adjusted EBITDA was $24.9 million, while the company reported a $15.5 million net loss. KLX said a rights offering re
M impact | EQUITY | Nov 06, 2026, 02:06 PM UTC
Universal Electronics Reports Q3 2026 Results, Plans Brazil Exit
Universal Electronics reported third-quarter 2026 net sales of $89.4 million versus $90.6 million a year earlier and GAAP operating income of $2.9 million, compared with a $4.5 mil
M impact | EQUITY | Nov 06, 2026, 02:05 PM UTC
Braemar Reports Q3 Results, Reaffirms 2027 Guidance and Plans Self-Management
Braemar reported comparable RevPAR up 14.4% and Hotel EBITDA up 20.7% to $12.9 million. It reaffirmed 2027 Adjusted EBITDAre guidance of $85 million to $90 million and NAREIT FFO o
M impact | EQUITY | Nov 06, 2026, 02:05 PM UTC